Examining unmet needs in infectious disease

Drug Discovery Today

Volumn 8, Issue 1, 2003, Pages 22-30

  Snell, Noel J C ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BIOLOGICAL WARFARE; DISEASE CONTROL; DISEASE RESISTANCE; ENCEPHALITIS; HANTAVIRUS PULMONARY SYNDROME; HEPATITIS VIRUS; HERPES VIRUS; IATROGENIC DISEASE; INFECTION; INFLUENZA; NIPAH VIRUS; NONHUMAN; PATHOGENICITY; REVIEW; RNA VIRUS; RNA VIRUS INFECTION; TRAVEL; TUBERCULOSIS; VIRUS HEMORRHAGIC FEVER; WEST NILE FLAVIVIRUS;

ANTI-INFECTIVE AGENTS; ANTIVIRAL AGENTS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; HUMANS; VIRUSES;

EID: 0037248519     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359644602025412     Document Type: Review

References (85)

1. Snell N.J.C. Emerging infectious diseases - a therapeutic challenge. Expert Opin. Pharmacother. 1:2000;363-365.
2. Dessleberger U. Emerging and re-emerging infectious diseases. J Infect. 40:2000;3-15.
3. Daszak P., et al. Emerging infectious diseases of wildlife - threats to biodiversity and human health. Science. 287:2000;443-449.
4. Patz J. A human disease indicator for the effects of recent global climate change. Proc. Natl. Acad. Sci. U. S. A. 99:2002;12506-12508.
5. Snell N.J.C. Bioterrorism today. Biologist. 49:2002;140.
6. Lorber B. Are all diseases infectious? Another look. Ann. Intern. Med. 131:1999;989-990.
7. Gura T. Chlamydia protein linked to heart disease. Science. 283:1999;1238-1239.
8. Staeheli P., Lieb K. Bornavirus and psychiatric disorders-fact or fiction? J. Med. Microbiol. 50:2001;579-581.
9. Lewis D. Retroviruses and the pathogenesis of schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 98:2001;4293-4294.
10. Benoist C., Mathis D. The pathogen connection. Nature. 394:1998;227-228.
11. Wolfson C., Talbot P. Bacterial infection as a cause of multiple sclerosis. Lancet. 360:2002;352-353.
12. Snell N.J.C., Davies P.D.O. New treatments for tuberculosis - whose responsibility? Int. J. Tuberc. Lung Dis. 1:(Suppl. 1):1997;50.
13. Fauci A. The AIDS epidemic. Considerations for the 21st century. N. Engl. J. Med. 341:1999;1046-1050.
14. De Clerq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficinecy virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. Med. Res. Rev. 16:1996;125-157.
15. Deeks S., et al. HIV-1 protease inhibitors: a review for clinicians. J. Am. Med. Assoc. 277:1997;145-153.
16. Palella F., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:1998;853-860.
17. Susman E. Many HIV patients carry mutated drug-resistant strains. Lancet. 359:2002;49.
18. Durant J., et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 353:1999;2159-2199.
19. Michael N., Moore J. HIV-1 entry inhibitors: evading the issue. Nat. Med. 5:1999;740-742.
20. McCarthy M. New HIV drugs show promise in early studies. Lancet. 359:2002;767.
21. Lieberman J., et al. Avoiding the kiss of death: how HIV and other chronic viruses survive. Curr. Opin. Immunol. 14:2002;478-486.
22. Hill R., et al. Vaginal microbicides for the prevention of HIV/AIDS: assessment of the potential market. Int. J. Pharm. Med. 14:2000;271-278.
23. Khanna K. Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J. Clin. Invest. 109:2002;205-211.
24. Martin-Serrano J., et al. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat. Med. 7:2001;1313-1319.
25. Stotsor V., Wolinsky S. GB virus C and mortality from HIV infection. N. Engl. J. Med. 345:2001;761-762.
26. Kauffmann G., et al. Potential benefit and limitations of a broad access to potent antiretroviral therapy in developing countries. Expert Opin. Investig. Drugs. 11:2002;1303-1313.
27. Letvin N. Strategies for an HIV vaccine. J. Clin. Invest. 109:2002;15-20.
28. McCormick J., et al. Lassa Fever: effective therapy with ribavirin. N. Engl. J. Med. 314:1986;20-26.
29. Baxter A. Symptomless infection with Ebola virus. Lancet. 355:2000;2178-2179.
30. Sullivan N. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 408:2000;605-609.
31. Freed E. Rafting with Ebola. Science. 296:2002;279.
32. Baribaud F., et al. The role of DC-SIGN and DC-SIGNR in HIV and Ebola virus infection: can potential therapeutics block virus transmission and dissemination? Expert Opin. Ther. Targets. 6:2002;423-431.
33. Peters C., Khan A. Hantavirus pulmonary syndrome: the new American haemorrhagic fever. Clin. Infect. Dis. 34:2002;1224-1231.
34. Huggins J., et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of haemorrhagic fever with renal syndrome. J. Infect. Dis. 164:1991;1119-1127.
35. Enserink M. Finally, a handle on the Hantaviruses. Science. 293:2001;1414-1415.
36. McCormack J., et al. Transmissibility from horses to humans of a novel paramyxovirus, equine morbillivirus (EMV). J. Infect. 38:1999;22-23.
37. Lam S., Chua K. Nipah virus encephalitis outbreak in Malaysia. Clin. Infect. Dis. 34:(Suppl. 2):2002;S48-S51.
38. Kelly D., Skidmore S. Hepatitis C-Z: recent advances. Arch. Dis. Child. 86:2002;339-343.
39. Lemon S., Thomas D. Vaccines to prevent viral hepatitis. N. Engl. J. Med. 336:1997;196-204.
40. Gow P., Mutimer D. Treatment of chronic hepatitis. Br. Med. J. 323:2001;1164-1167.
41. Farrell G. Clinical potential of emerging new agents in hepatitis B. Drugs. 60:2000;701-710.
42. Moradpour D., et al. Hepatitis C: molecular virology and antiviral targets. Trends Mol. Med. 8:2002;476-482.
43. Patel K., McHutchison J. Peginterferon alpha-2b: a new approach to improving response in hepatitis C patients. Expert Opin. Pharmacother. 2:2001;1307-1315.
44. Cheng S., et al. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology. 33:2001;231-240.
45. Dymock B. Emerging drugs for hepatitis C infection. Emerg. Drugs. 6:2001;13-42.
46. Hall C.B. Human herpesviruses at sixes, sevens, and more. Ann. Intern. Med. 127:1997;481-483.
47. Chamberland M. Emerging infectious agents: do they pose a risk to the safety of transfused blood and blood products? Clin. Infect. Dis. 34:2002;797-805.
48. Drucker E., et al. The injection century: massive unsterile injections and the emergence of human pathogens. Lancet. 358:2001;1989-1992.
49. Stenton S. Simian virus 40 and human malignancy. Br. Med. J. 316:1998;877.
50. Malkin D. Simian virus 40 and non-Hodgkin lymphoma. Lancet. 359:2002;812-813.
51. Nakata K., et al. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am. J. Respir. Crit. Care Med. 155:1997;996-1003.
52. Dye C., et al. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science. 295:2002;2042-2046.
53. Snell N. The treatment of tuberculosis: current status and future prospects. Expert Opin. Invest. Drugs. 7:1998;545-552.
54. Khasnobis S., et al. Emerging therapeutic targets in tuberculosis: post-genomic era. Expert Opin. Ther. Targets. 6:2002;21-40.
55. Johnston N. Viral Trojan horse for combating tuberculosis. Drug Discov. Today. 7:2002;333-335.
56. Schluger N. Recent advances in our understanding of human host responses to tuberculosis. Respir. Res. 2:2001;157-163.
57. Doherty T., Andersen P. Tuberculosis vaccine development. Curr. Opin. Pulm. Med. 8:2002;183-187.
58. Meek J. West Nile virus in the United States. Curr. Opin. Paediatr. 14:2002;49-52.
59. Snow K., Ramsdale C. Mosquitoes and tyres. Biologist. 49:2002;49-52.
60. Pletnev A., et al. West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc. Natl. Acad. Sci. U. S. A. 99:2002;3036-3041.
61. Gibbons R., Vaughn D. Dengue: an escalating problem. BMJ. 324:2002;1563-1566.
62. Halstead S., Deen J. The future of Dengue vaccines. Lancet. 360:2002;1243-1245.
63. Management of herpes virus infections following transplantation. J. Antimicrob. Chemother. 45:2000;729-748.
64. Bogner E. Human cytomegalovirus terminase as a target for antiviral chemotherapy. Rev. Med. Virol. 12:2002;115-127.
65. Crumpacker C., Schaffar P. New anti-HSV therapeutics target the helicase-primase complex. Nat. Med. 8:2002;327-328.
66. Snell N.J.C. New treatments for viral respiratory tract infections - opportunities and problems. J. Antimicrob. Chemother. 47:2001;251-259.
67. Chan P. Outbreak of avian influenza A (H5N1) virus infection in Hong Kong in 1997. Clin. Infect. Dis. 34:(Suppl. 2):2002;S58-S64.
68. Palese P. Influenza vaccines: present and future. J. Clin. Invest. 110:2002;9-13.
69. Kern E., et al. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 46:2002;991-995.
70. Leppla S., et al. Development of an improved vaccine for anthrax. J. Clin. Invest. 109:2002;141-144.
71. Smith R., Coast J. Antimicrobial resistance: a global response. Bull. WHO. 80:2002;126-133.
72. Kortoyiannis D., Lewis R. Antifungal drug resistance of pathogenic fungi. Lancet. 359:2002;1135-1144.
73. area of investigation. J. Antimicrob. Chemother. 49, 597-599.
74. Sefton A. Mechanisms of antimicrobial resistance: their clinical relevance in the new milennium. Drugs. 62:2002;557-566.
75. Wendo C. African scientists discuss drug-resistant malaria. Lancet. 359:2002;770.
76. Ferber D. Livestock feed ban preserves drugs' power. Science. 295:2002;27-28.
77. Roccanova L., Rappa P. Antibiotic rotation. Science. 287:2000;803.
78. Hodgkinson R., Sharples D. Reversing antibiotic resistance. Expert Opin. Investig Drugs. 11:2002;1023-1032.
79. Tan Y.-T., et al. Molecular strategies for overcoming antibiotic resistance in bacteria. Mol. Med. Today. 6:2000;309-314.
80. Kaneko T., et al. New antibacterials for resistant organisms. Annu. Rep. Med. Chem. 34:1999;169-178.
81. Beyer D., Pepper K. The streptogramin antibiotics: update on their mechanism of action. Expert Opin. Investig. Drugs. 7:1998;591-599.
82. Nathanson N., Fine P. Poliomyelitis eradication - a dangerous endgame. Science. 296:2002;269-270.
83. Lockwood D. Leprosy elimination - a virtual phenomenon or a reality? Br. Med. J. 324:2002;1516-1518.
84. Wilson M. Infectious diseases: an ecological perspective. Br. Med. J. 311:1995;1681-1684.
85. Sela M., et al. Therapeutic vaccines: realities of today and hopes for the future. Drug Discov. Today. 7:2002;664-673.